Mode
Text Size
Log in / Sign up

Seasonal influenza vaccine effectiveness increased against A(H3N2) and B strains in post-pandemic periodFlu vaccine effectiveness shows changes after the COVID-19 pandemic

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note higher post-pandemic vaccine effectiveness against A(H3N2) and influenza B across multiple age groups.

This meta-analysis synthesized data from 85 publications to evaluate seasonal influenza vaccine effectiveness (VE) in the Northern Hemisphere across different age groups. The analysis compared the pre-pandemic period (2010/11-2019/20) with the post-pandemic period (2022/23-2024/25).

Key findings indicate higher VE against A(H3N2) in 6-month-17-year-olds (53% [42-64%] vs. 37% [30-45%]) and 18-64-year-olds (35% [25-45%] vs. 21% [13-29%]). Additionally, VE against influenza B was higher in both the 6-month-17-year-old group (85% [78-93%] vs. 52% [45-60%]) and the 18-64-year-old group (73% [59-87%] vs. 49% [41-57%]). Conversely, VE against A(H1N1)pdm09 in 18-64-year-olds was lower post-pandemic (37% [27-46%]) compared to pre-pandemic (55% [47-62%]).

The authors noted that data for B/Victoria were limited. While the results suggest higher VE in the post-pandemic period, the authors cautioned that factors other than population immunity may explain these observations. The findings provide evidence of a shift in vaccine performance but do not establish a direct causal link to specific pandemic-related changes.

How this fits prior evidence

This meta-analysis provides new data on seasonal influenza vaccine effectiveness (VE) trends following the COVID-19 pandemic. It addresses gaps regarding current vaccine performance by comparing post-pandemic results to historical data, showing higher VE for A(H3N2) and B strains. This follows previous coverage noting that pregnancy increases influenza susceptibility and severity, emphasizing the importance of vaccination in high-risk groups.

When we think about the flu, we often focus on how well our annual shots protect us. A review of 85 publications across the Northern Hemisphere shows some interesting shifts in how these vaccines performed before and after the COVID-19 pandemic.

For many people, the vaccine was more effective against influenza B and the H3N2 strain in recent years. For example, among children and teens, protection against influenza B jumped from 52% to 85%. Adults also saw a jump in protection against H3N2, rising from 21% to 35%. However, the results were mixed for other strains; protection against A(H1N1)pdm09 actually dropped from 55% to 37% in adults.

It is important to note that these findings show a link between the time period and vaccine success, but they do not prove exactly why this happened. Other factors beyond just population immunity could be at play. Because of these complexities, talk to your doctor about how the flu shot works for you.

What this means for you:
Flu vaccines showed higher effectiveness against H3N2 and influenza B since the COVID-19 pandemic began.

Common questions

How effective is the flu vaccine for children?

The data shows that for children aged 6 months to 17 years, the vaccine was more effective against the H3N2 strain (53% compared to 37%) and significantly more effective against influenza B (85% compared to 52%) in the post-pandemic period.

Is the flu vaccine more effective for adults now?

For adults aged 18 to 64, the vaccine showed higher effectiveness against H3N2 (35% compared to 21%) and influenza B (73% compared to 49%) in the post-pandemic period. However, protection against A(H1N1)pdm09 was lower than before.

Why did the vaccine effectiveness change?

While the data shows a link between the post-pandemic period and higher effectiveness for some strains, researchers note that other factors besides population immunity could explain these differences. You should speak with a healthcare provider about your specific needs.

Study Details

Study typeMeta analysis
EvidenceLevel 1
Follow-up6.0 mo
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Influenza circulation was substantially reduced during the COVID-19 pandemic. The consequent reduction in population immunity may have resulted in increased influenza vaccine effectiveness (VE) after the pandemic via reduced immunity in unvaccinated individuals compared to the pre-pandemic period. METHODS: We systematically reviewed published peer-reviewed test-negative design (TND) studies of seasonal influenza VE against medically-attended, laboratory-confirmed influenza in the Northern Hemisphere. We compared pooled VE estimates before (2010/11-2019/20) and after (2022/23-2024/25) the COVID-19 pandemic (defined as 2020/21-2021/22). Pooled VE against A(H1N1)pdm09, A(H3N2), influenza B, and B/Victoria was calculated for three age groups (6 months-17 years, 18-64 years, ≥65 years) using inverse-variance random-effects meta-analysis. Heterogeneity was quantified with the I statistic, and differences between pooled VE estimates pre- and post-pandemic periods were tested with the χ statistic. RESULTS: Eighty-five publications were included. Post-pandemic VE against A(H3N2) was significantly higher than pre-pandemic VE in 6-month-17-year-olds (53% [42-64%] vs 37% [30-45%]) and 18-64-year-olds (35% [25-45%] vs 21% [13-29%]). Similarly, VE against influenza B was higher post-pandemic in both age groups (85% [78-93%] vs 52% [45-60%] and 73% [59-87%] vs 49% [41-57%], respectively). Conversely, VE against A(H1N1)pdm09 was lower post-pandemic in 18-64-year-olds (37% [27-46%] vs 55% [47-62%]). No significant differences were observed for ≥65-year-olds, and data for B/Victoria were limited. CONCLUSIONS: The evidence suggests slightly higher VE against seasonal influenza after the COVID-19 pandemic although there may be factors other than population immunity that may explain our observations.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.